

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Empliciti (elotuzumab)

Override	Approval Duration
Prior Authorization	1 year

Medication
Empliciti (elotuzumab)

APPROVAL CRITERIA

Requests for Empliciti (elotuzumab) may be approved if the following criteria are met:

- I. Individual has a diagnosis of relapsed, progressive, or refractory multiple myeloma, including plasma-cell leukemia; **AND**
- II. Individual has not received prior lines of therapy which included elotuzumab; **AND**
- III. Individual is using in combination with one of the following:
 - A. Lenalidomide and dexamethasone; **OR**
 - B. Bortezomib and dexamethasone; **OR**
 - C. Pomalidomide and dexamethasone (in individuals who have received at least two prior therapies including lenalidomide and a proteasome inhibitor).

Requests for Empliciti (elotuzumab) may not be approved when the above criteria are not met, including but not limited to treatment for a diagnosis other than multiple myeloma or plasma-cell leukemia.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: March 13, 2019.

PAGE 1 of 2 11/06/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0458-19

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on March 13, 2019.
 - a. Multiple Myeloma. V2.2019. Revised November 16, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.